Last reviewed · How we verify
Deramiocel (CAP-1002)
Deramiocel is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and reduces inflammation following myocardial injury.
Deramiocel is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and reduces inflammation following myocardial injury. Used for Acute myocardial infarction with reduced ejection fraction, Duchenne muscular dystrophy-associated cardiomyopathy.
At a glance
| Generic name | Deramiocel (CAP-1002) |
|---|---|
| Also known as | Allogeneic Cardiosphere-Derived Cells, Cardiosphere-Derived Cells (CDCs) |
| Sponsor | Capricor Inc. |
| Drug class | Allogeneic cell therapy |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
CAP-1002 consists of cardiosphere-derived cells (CDCs) derived from donated heart tissue that are expanded ex vivo and administered to patients with cardiac damage. These cells work through paracrine mechanisms—secreting anti-inflammatory cytokines and growth factors—to reduce fibrosis, promote angiogenesis, and preserve cardiac function. The therapy aims to regenerate damaged myocardium and prevent progressive heart failure.
Approved indications
- Acute myocardial infarction with reduced ejection fraction
- Duchenne muscular dystrophy-associated cardiomyopathy
Common side effects
- Pericardial effusion
- Arrhythmia
- Infection at injection site
- Chest pain
Key clinical trials
- A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE3)
- Open-label Extension of the HOPE-2 Trial (PHASE2)
- A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |